Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2104374 | 0.83 | — | — | |
| SCHEMBL4960198 | 0.77 | — | — | |
| SCHEMBL6310576 | 0.75 | — | — | |
| SCHEMBL13924051 | 0.75 | MAPK1 (0.33) | — | |
| SCHEMBL15474301 | 0.74 | — | — | |
| SCHEMBL13931719 | 0.72 | — | — | |
| SCHEMBL21351148 | 0.71 | — | — | |
| SCHEMBL19484518 | 0.70 | — | — | |
| SCHEMBL5172749 | 0.70 | — | — | |
| SCHEMBL21246419 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025021955-A1 | PROCESS FOR PREPARING ENDO-UNSATURATED 1,3-DIOXOL-2-ONES | BASF SE (DE) | 2025-01-30 | — | — | WO | disclosed |
| US-20230295089-A1 | ANTIPLATELET DRUGS AND USES THEREOF | SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-9771320-B2 | Carbocyclic sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9732080-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160326103-A1 | CARBOCYCLIC SULFONE ROR GAMMA MODULATORS | BRISTROL-MYERS SQUIBB COMPANY (US) | 2016-11-10 | — | — | US | disclosed |
| US-20150336956-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARAMCEUTICALS INCORPORATED | 2015-11-26 | — | — | US | disclosed |
| US-9102672-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-08-11 | — | — | US | disclosed |
| US-8722255-B2 | Non-aqueous electrolytic solution for lithium secondary battery and lithium secondary battery using the same | UBE INDUSTRIES, LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20140024672-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563573-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120183864-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY USING THE SAME | UBE INDUSTRIES, LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-8163427-B2 | Nonaqueous electrolytic solution for lithium secondary battery and lithium secondary battery using the same | UBE INDUSTRIES, LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2369670-A1 | Non-aqueous electrolytic solution for lithium secondary battery and lithium secondary battery using the same | Ube Industries, Ltd. (JP) | 2011-09-28 | — | — | EP | disclosed |
| US-20090253736-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-08 | — | — | US | disclosed |
| US-20060177742-A1 | Nonaqueous electrolytic solution for lithium secondary battery and lithium secondary battery using the same | MU IONIC SOLUTIONS CORPORATION (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1650826-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY USING SAME | Ube Industries, Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024672-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCC2 | ALDH1A1 1724/4885MAPT 4837/4885MCL1 4392/4885 |
| US-20160326103-A1 | CARBOCYCLIC SULFONE ROR GAMMA MODULATORS | RORC, RORB, RORA | ALDH1A1 1062/4885MAPT 915/4885MCL1 1067/4885 |
| US-20150336956-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCC2 | ALDH1A1 1724/4885MAPT 4837/4885MCL1 4392/4885 |
| US-20230295089-A1 | ANTIPLATELET DRUGS AND USES THEREOF | PFKP, GP6, PF4 | ALDH1A1 734/4885MAPT 4539/4885MCL1 1928/4885 |
| US-20090253736-A1 | AZAINDOLE DERIVATIVES AS CFTR MODULATORS | CFTR, ABCB1, ABCC2 | ALDH1A1 1724/4885MAPT 4837/4885MCL1 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.